LV10451B - Benzocycloheptenes, benzoxepines and benzothiepines and methods for preparation thereof - Google Patents

Benzocycloheptenes, benzoxepines and benzothiepines and methods for preparation thereof Download PDF

Info

Publication number
LV10451B
LV10451B LVP-94-154A LV940154A LV10451B LV 10451 B LV10451 B LV 10451B LV 940154 A LV940154 A LV 940154A LV 10451 B LV10451 B LV 10451B
Authority
LV
Latvia
Prior art keywords
pyridyl
oxide
dimethyl
dihydro
benzoxepine
Prior art date
Application number
LVP-94-154A
Other languages
English (en)
Other versions
LV10451A (lv
Inventor
Berthelon Jean-Jacques
Brunet Michel
Noblet Marc
Durbin Philippe
Guerrier Daniel
Luong Trong Nghia
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of LV10451A publication Critical patent/LV10451A/lv
Publication of LV10451B publication Critical patent/LV10451B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Resins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (14)

  1. LV 10451 BENZOCIKLOHEPTĒNI, BENZOKSEPĪNI UN BENZOTIEPĪNI, TO IEGŪŠANAS METODES PATENTA FORMULA 1. Savienojumi ar vispārēju formulu:
    kurā: X simbolizē 0 vai CHR, kur R ir ūdeņraža atoms vai R, savienots ar Rit veido saiti, Rl, R2, R3 un R4, kas ir vienādi vai atšķirīgi, simbolizē ūdeņraža atomu vai Ci-C7-alkilgrupu; ir iespējams, ka Ri papildus veido saiti ar R; R5 simbolizē ūdeņraža atomu, hidroksilgrupu vai R5, savienots ar R7, veido saiti vai yO grupu; R6 simbolizē grupu ar formulu: ✓*10 "C^R RU kurā R10 un Rn, savienoti ar oglekļa atomu, kuram tie piesaistīti, veido neobligāti aromātisku mono- vai biciklisku slāpekli saturošu heterociklisku grupu ar 3 līdz 11 locekļiem, kas ietver 1 vai 2 slāpekļa atomus, neobligāti aizvietotu pie oglekļa atomiem ar 1 līdz 7 grupām, kas izvēlētas no hidroksil-, nitro-, ciano-, Ci-C7*alkil- vai Ci-C7-alkoksigrupām; ir iespējams, ka vismaz viens no heterocikla slāpekļa atomiem ir N-oksidēts; R7 simbolizē ūdeņraža atomu vai hidroksil-, Ci-C7-alkoksi- vai C1-C7--aciloksigrupu vai R5 un R7 kopā veido saiti vai >0 grupu; R8 un R9, kas ir vienādi vai atšķirīgi, simbolizē ūdeņraža vai halogēna atomu, hidroksil-, nitro-, ciano-, trifluormetil-, trifluormetoksi-, pentafluoretil-, Cļ-C7-alkil-, Ci-C7-alkoksi-, Ci-C7-alkiltio-, C1-C7- 2 -aciltio-, Ci-C7-alkilsulfonil- vai Ci-C7-alkilsulfinilgrupu, grupu ar formulām: 0 0 O -C-OR12, -C-NR12R13 vai -C-R12 kurās R12 un R13, kas ir vienādi vai atšķirīgi, simbolizē ūdeņraža atomu vai Ci-C7-alkilgrupu, vai Re un R9 simbolizē Ce-Cio-aril-, (C6-Cio)arilsulfonil- vai (C6-Ci(y)arilsulfinilgrupu, neobligāti aizvietotu ar vienu līdz sešiem aizvietotājiem, kas izvēlēti no halogēna, hidroksil-, nitro-, ciano-, karboksil-, karbamoil-, trifluormetil-, trifluormetoksi-, pentafluoretil-, Ci-C7-alkil-, C1-C7--alkoksi-, Ci-C7-alkiltio-, Ci-C7-aciltio-, Ci-C7-alkilsulfonil- vai Ci-C7-alkilsulfinilgrupām, vai Rg un Rg, kas ir vienādi vai atšķirīgi, simbolizē heterociklu ar 3 līdz 11 locekļiem gredzenā, ietverot 1 līdz 4 heteroatomus, kas ir vienādi vai atšķirīgi un izvēlēti no O, S un N, neobligāti aizvietotu ar vienu līdz sešiem aizvietotājiem, kas izvēlēti no halogēna, hidroksil-, nitro-, ciano-, karboksil-, karbamoil-, trifluormetil-, trifluormetoksi-, pentafluoretil-, Ci-C7*alkil-, Ci-C7-alkoksi-, Ci-C7-alkiltio-, Ci-C7-aciltio-, Ci-C7-alkilsulfonil- vai C1-C7--alkilsulfinilgrupām, vai Rg un Rg kopā veido grupu (CH2)n> kur n ir skaitlis 1 līdz 6, vai Rg un Rg kopā veido heterociklu ar 3 līdz 11 locekļiem, ietverot 1 līdz 4 heteroatomus, kas ir vienādi vai atšķirīgi un izvēlēti no 0, S un N, neobligāti aizvietotu ar vienu līdz sešiem aizvietotājiem, kas izvēlēti no halogēna, hidroksil-, nitro-, ciano-, karboksil-, karbamoil-, trifluormetil-, trifluormetoksi-, pentafluoretil-, C1-C7-alkil-, Ci-C7-alkoksi-, Ci-C7-alkiltio-, Ci-C7-aciltio-, Ci-C7-alkil-sulfonil- vai C1-C7- alkilsulfinilgrupām, un to N-oksīdi, un to farmakoloģiski saderīgi sāļi.
  2. 2. Savienojumi ar vispārējo formulu I, saskaņā ar 1. punktu, atšķirīgi ar to, ka X simbolizē skābekļa atomu.
  3. 3. Savienojumi ar vispārējo formulu I, saskaņā ar 1. punktu, atšķirīgi ar to, ka Ri un R2 simbolizē ūdeņraža atomu. 3 LV 10451
  4. 4. Savienojumi ar vispārējo formulu I, saskaņā ar 1. punktu, atšķirīgi ar to, ka R5 simbolizē ūdeņraža atomu.
  5. 5. Savienojumi ar vispārējo formulu I, saskaņā ar 1. punktu, atšķirīgi ar to, ka Re ir izvēlēts no 2-piridilgrupas, 2-piridil-N-oksīda, 3-piridilgrupas, 3-piridil-N-oksīda, 4-piridilgrupas, 3-hidroksi-4--piridilgrupas, 2-pirimidilgrupas, 2-pirimidil*N-oksida, 6-pirimidil-grupas, 6-pirimidil-N-oksida, 2-hinolilgrupas, 2-hinolil-N-oksīda, 1-izohinolilgrupas un 1-izohinolil-N-oksīda, neobligāti aizvietotiem pie oglekļa atomiem ar 1 līdz 3 aizvietotājiem, kas izvēlēti no hidroksil-, nitro-, ciano-, Ci-C7-alkil- un Ci-C7-alkoksigrupām.
  6. 6. Savienojumi ar vispārējo formulu I, saskaņā ar 1. punktu, atšķirīgi ar to, ka R7 simbolizē ūdeņraža atomu vai hidroksil-, metoksi- vai acetoksigrupu.
  7. 7. Savienojumi, saskaņā ar 1. punktu, ar vispārēju formulu:
    II kurā X simbolizē 0 vai CHR, un R, R5, Re, R7, Re un Rg ir, kā noteikts 1. punktā.
  8. 8. Savienojumi, saskaņā ar 1. punktu, ar vispārēju formulu:
    kurā X simbolizē O vai CHR, un R, Ū6, R8 un Rg ir, kā noteikts 1. punktā. III 4
  9. 9. Savienojumi, saskaņā ar 1. punktu, atšķirīgi ar to, ka tie izvēlēti no savienojumiem: 3.3- dimetil-5-(2-piridil-N-oksīd)-7-trifluormetoksi-2,3-dihidro-l-benzo-ksepīns; 3.3- dimetil-5-(2-piridil-N-oksīd)-2,3-dihidro-l-benzoksepīns; 7-fluor-3,3-dimetil-5-(2-piridil-N-oksīd)-2,3-dihidro-l-benzoksepīns; 7- brom-3,3-dimetil-5-(2-piridil-N-oksīd)-2,3-dihidro-l-benzoksepīns; 8- brom-3,3,7-trimetil-5-(2-piridil*N-oksīd)-2,3-dihidro-l-benzoksepīns; 7-etil-3,3-dimetil-5-(2-piridil-N-oksid)-2,3-dihidro-l-benzoksepins; 3.3- dimetil-5-(2-piridil-N-oksīd)-7-(l-metilpropil)-2,3-dihidro-l-benzo-k ksepins; 7dzopropil-3,3-dimetil-5-(2-piridil-N-oksid)-2,3-dihidro-l-benzoksepins; 7- metoksi-3,3'dimetil-5-(2-piridil-N-oksTd)-2,3-dihidro-l-benzoksepīns; 3.3- dimetil-5-(2-piridil-N-oksīd)-7-metilsulfinil-2,3-dihidro-l-benzo-ksepīns; 3.3- dimetil-5-(2-piridil-N-oksīd)-7-metilsulfonil-2,3-dihidro-l-benzo-ksepīns; 3.3- dimetil-5-(2-piridil-N-oksid)-7-pentafluoretil-2,3-dihidro-l-benzo-ksepins; 3.3- dimetil-5-(2-piridil-N-oksīd)-7-trifluormetil-2,3-dihidro-l-benzo-ksepins; 8- brom-3,3-dimetil-5-(2-piridil-N-oksīd)-2,3-dihidro-l-benzoksepīns; 7- brom-3,3-dimetil-5-(3-piridil-N-oksīd)-2,3-dihidro-l-benzoksepīns; 3.3- dimetil-7-nitro-5-(4-nitro-2-piridil-N-oksīd)-2,3-dihidro-l-benzo-ksepīns; 3.3- dimetil-7-fenil-5-(2-piridil*N-oksīd)-2,3-dihidro-l-benzoksepīns; 8- ciano-3,3-dimetil-5-(2-piridil-N-oksid)-2,3-dihidro-l-benzoksepins; 6.8- dihlor-3,3-dimetil-5-(2-piridil-N-oksīd)-2,3-dihidro-l-benzoksepīns; 7.9- dihlor-3,3-dimetil-5-(2-piridil-N-oksīd)-2,3-dihidro-l-benzoksepīns; 8.9- dihlor-3,3-dimetil-5-(2-piridil-N-oksīd)*2,3-dihidro-l-benzoksepīns; 7,8-dimetoksi-3,3-dimetil-5-(2-piridil-N-oksīd)-2,3-dihidro-l-benzokse-pīns; 9- etil-7-fluor-3,3-dimetil-5-(2-piridil-N-oksīd)-2,3-dihidro-l-benzoksepīns; 7-hlor-8-fluor*3,3-dimetil-5-(2-piridil-N-oksīd)-2,3-dihidro-l-benzokse-pīns; 3.3- dimetil-5-(2-piridil-N-oksīd)-2,3,7,8,9,10-heksahidro-l-naftr2,3--bjoksepīns; 5 LV 10451 7.8- dihlor-3,3-dimetil-5-(2-piridil-N-oksīd)-2,3-dihidro-l-benzoksepin-5--ols; 7- hlor-8-etil-3,3-dimetil-5-(2-piridil-N-oksid)-2,3-dihidro-l-benzoksepins; un 8- brom-3,3-dimetil-l-(2-piridil-N-oksīd)-3H-benzo[f]-ciklohepta-l,4--diēns.
  10. 10. Savienojumi, saskaņā ar 1. punktu, atšķirīgi ar to, ka tie izvēlēti no savienojumiem: 7-hlor-3,3-dimetil-5-(2-piridil-N-oksīd)-2,3-dihidro-l-benzoksepins; 3.3- dimetil-5-(2-piridil*N-oksīd)*7-trifluormetil-2,3-dihidro-l-benzo-ksepīns; 7- ciano-3,3-dimetil-5-(2-piridil-N-oksid)-2,3-dihidro-l-benzoksepīns; 8- ciano-3,3-dimetil-l-(2-piridil-N-oksid)-4,5-dihidro-3H-benzo[f]ciklo-heptēns; 7.8- dihlor-3,3-dimetil-5-(2-piridil-N-oksīd)-2,3-dihidro-l-benzoksepins; 7.8- diiluor-3,3-dimetil-5-(2-piridil-N-oksid)-2,3-dihidro-l-benzoksepins; 7- ciano-3,3,8-trimetil-5-(2-piridil-N-oksīd)-2,3-dihidro-l-benzoksepins; 8- ciano-3,3,7-trimetil-5-(2-piridil-N-oksid)-2,3-dihidro-l-benzoksepīns; 3.3- dimetil-5-(2-piridil-N-oksīd)-2,3-dihidro-l-benzoksepīn-7-karboksi-amīds; un 3.3- dimetil-7-fenilsulfonil-5-(2-piridil-N-oksīd)-2,3-dihidro-l-benzo-ksepīns.
  11. 11. Metode savienojumu ar vispārēju formulu I:
    kurā: 6 X simbolizē O vai CHR, kur R ir ūdeņraža atoms vai R, savienots ar Ri( veido saiti, Ri, R2, R3 un R4, kas ir vienādi vai atšķirīgi, simbolizē ūdeņraža atomu vai C1-C7 - alkilgrupu; ir iespējams, ka Ri papildus veido saiti ar R; R5 simbolizē ūdeņraža atomu, hidroksilgrupu vai R5, savienots ar R7, veido saiti vai X) grupu;
    Re simbolizē grupu ar formulu: kurā R10 un Rn, savienoti ar oglekļa atomu, kuram tie piesaistīti, veido neobligāti aromātisku mono- vai biciklisku slāpekli saturošu heterociklisku grupu ar 3 līdz 11 locekļiem, ietverot 1 vai 2 slāpekļa atomus, neobligāti aizvietotu pie oglekļa atomiem ar 1 līdz 7 grupām, kas izvēlētas no hidroksil-, nitro-, ciano·, Ci-C7-alkil- vai Cļ-C7-alkoksigrupām; ir iespējams, ka vismaz viens heterocikla slāpekļa atoms ir N-oksidēts; R7 simbolizē ūdeņraža atomu vai hidroksil-, Ci-C7-alkoksi- vai C1-C7--aciloksigrupu vai R5 un R7 kopā veido saiti vai >0 grupu; Re un Rg, kas ir vienādi vai atšķirīgi, simbolizē ūdeņraža vai halogēna atomu, hidroksil-, nitro-, ciano-, trifluormetil-, trifluormetoksi-, pentafluoretil-, Ci-C7-alkil-, Ci-C7-alkoksi-, Ci-C7-alkiltio-, C1-C7--aciltio-, Ci-C7-alkilsulfonil- vai Ci-C7-alkilsulfmilgrupu, grupu ar formulām: O 0 0 O -C-OR12, -0-NRi2Rl3 vai -C-R12 kurās R12 un R13, kas ir vienādi vai atšķirīgi, simbolizē ūdeņraža atomu vai Ci-C7-alkilgrupu, vai Rs un Rg simbolizē Ce-Cio-aril-, (C6-Cio)arilsulfonil- vai (C6-Cio)arilsulfinilgrupu, neobligāti aizvietotu ar vienu līdz sešiem aizvietotājiem, kas izvēlēti no halogēna, hidroksil-, nitro-, ciano-, karboksil-, karbamoil-, trifluormetil-, trifluormetoksi-, pentafluoretil-, Ci-C7-alkil-, C1-C7--alkoksi-, Ci-C7-alkiltio-, Ci-C7-aciltio-, Ci-C7-alkilsulfonil- vai C1 -C7-alkilsulfinilgrupām, LV 10451 vai Re un Rg, kas ir vienādi vai atšķirīgi, simbolizē heterociklu ar 3 līdz 11 locekļiem gredzenā, ietverot 1 līdz 4 heteroatomus, kas ir vienādi vai atšķirīgi un izvēlēti no 0, S un N, neobligāti aizvietotu ar vienu līdz sešiem aizvietotājiem, kas izvēlēti no halogēna, hidroksil-, nitro-, ciano-, karboksil-, karbamoil-, trifluormetil-, trifluormetoksi-, pentafluoretil-, Ci-C7-alkil-, Cļ-C7-alkoksi-, Ci-C7-alkiltio-, Ci-C7-aciltio-, Ci-C7-alkilsulfonil- vai Ci-C7-alkil-sulfinilgrupām, vai Re un Rg kopā veido grupu (CH2)n, kur n ir skaitlis 1 līdz 6, vai R8 un Rg kopā veido heterociklu ar 3 līdz 11 locekļiem, ietverot 1 līdz 4 hetferoatomus, kas ir vienādi vai atšķirīgi un izvēlēti no 0, S un N, neobligāti aizvietotu ar vienu līdz sešiem aizvietotājiem, kas izvēlēti no halogēna, hidroksil-, nitro-, ciano-, karboksil-, karbamoil-, trifluormetil-, trifluormetoksi-, pentafluoretil-, Ci-C7-alkil-, Ci-C7-alkoksi-, Ci-C7-alkiltio-, Ci-C7-aciltio-, C1-C7 -alkilsulfonil-vai Ci-C7-alkilsulfinilgrupām, un to farmakoloģiski saderīgu sāļu un N-oksīdu iegūšanai, atšķirīga ar to, ka ietver: jebkuru: a) ketona ar vispārēju formulu IV
    IV kurāX, Ri, R2, R3 un R4 ir, kā noteikts iepriekš, unRs’, Rs' un Rg’ attiecīgi simbolizē neobligāti aizsargātas R5, Rs un R9 grupas, kā noteikts iepriekš, reakciju ar metālorganisku savienojumu ar vispārēju formulu: Re * Rm V
    kurā Rg' simbolizē grupu ar formulu: 8 kurā Rio un Rn, savienoti ar oglekļa atomu, kuram tie ir piesaistīti, veido neobligāti aromātisku mono- vai biciklisku, slāpekli saturošu heterociklisku grupu ar 3 līdz 11 locekļiem, ieskaitot 1 vai 2 slāpekļa atomus, un neobligāti aizvietotu pie oglekļa atomiem ar 1 līdz 7 grupām, kas ir neobligāti aizsargātas, ja nepieciešams, un izvēlētas no hidroksil-, nitro-, ciano-, Ci*C7-alkil- vai Ci-C7-alkoksigrupām un b) aizsarggrupu atšķelšanu, lai iegūtu savienojumu ar vispārēju formulu VI:
    VI kurā X, Ri, R2, R3, R4, R5, R6, Rs un R$ ir, kā noteikts iepriekš; un neobligāti jebkuru: cl) tādā veidā iegūtā savienojuma ar vispārēju formulu VI reakciju ar reaģentu ar vispārēju formulu VII: VII Rl4-Y kurā R14 simbolizē Ci-C7-alkil- vai Ci-C7-acilgrupu un Y simbolizē atšķeļamo grupu, lai iegūtu savienojumu ar vispārējo formulu I, kurā R7 simbolizē attiecīgi Ci-C7-alkoksi- vai Ci-C7-aciloksigrupu; vai c2) savienojuma ar vispārējo formulu VI, kas iegūts pēc metodes b), dehidratēšanu skābes vai skābes hlorīda klātbūtnē, lai iegūtu savienojumu ar sekojošu vispārējo formulu I:
    I 9 LV 10451 kurā X, Rļ, R2, R3, R4, R5, R6, Rs un Rg ir, kā noteikts iepriekš; un neobligāti d) savienojuma ar formulu I, kas iegūts stadijā c2), reakciju ar peroksīdu, lai iegūtu savienojumu ar vispārējo formulu I, kurā R5 un R7 kopā veido >0 grupu; un neobligāti e) savienojuma ar vispārējo formulu VI, kas iegūts stadijā b), vai savienojuma ar vispārējo formulu I, kas iegūts stadijā cl), c2) vai d), reakciju ar oksidējošu aģentu, lai veidotu atbilstošu N-oksīda savienojumu; un/vai neobligāti f) savienojuma ar vispārēju formulu VI, kas iegūts stadijā b), vai savienojuma ar vispārējo formulu I, kas iegūts stadijā cl), c2) vai d), reakciju ar farmācijā izmantojamu neorganisku vai organisku skābi, lai veidotu atbilstošu sāli.
  12. 12. Farmaceitisks sastāvs, kas kā aktīvo sastāvdaļu satur savienojumu, saskaņā ar jebkuru no 1. līdz 10. punktiem.
  13. 13. Savienojumi ar formulu
    VIII kurā X, Ri, R2, R3, R4, R5, Re un R9 ir, kā noteikts 1. punktā.
  14. 14. Savienojumi, kas izvēlēti no sekojošiem savienojumiem: 4-fenoksi-3,3-dimetilbutānskābe; 4-(4-bromfenoksi)-3,3-dimetilbutānskābe; 4-(4-hlorfenoksi)-3,3-dimetilbutānskābe; 4-(4-fluorfenoksi)-3,3-dimetilbutānskābe; 4-(4-metilfenoksi)-3,3-dimetilbutānskābe; 4-(4-etilfenoksi)-3,3-dimetilbutānskābe; 4-(4-izopropilfenoksi)-3,3-dimetilbutānskābe; 4-[4-(l-metilpropil)fenoksi]-3,3-dimetilbutānskābe; 4-(4-metoksifenoksi)-3,3-dimetilbutānskābe; 10 4-(4-trifluormetoksifenoksi)-3,3-dimetilbutānskābe; 4-(4-metiltiofenoksi)-3,3-dimetilbutānskābe; 4-(4-fenilfenoksi)-3,3-dimetilbutānskābe; 4-(3-bromfenoksi)-3,3-dimetilbutānskābe; 4-(3,5-dihlorfenoksi)-3,3-dimetilbutānskābe; 4-(3,4-dihlorfenoksi)-3,3-dimetilbutānskābe; 4-(2,4-dihlorfenoksi)-3,3-dimetilbutānskābe; 4-(2,3-dihlorfenoksi)-3,3-dimetilbutānskābe; 4-(3,4-difluorfenoksi)-3,3-dimetilbutānskābe; 4-(3-hlor-4-fluorfenoksi)-3,3-dimetilbutānskābe; 4-(2-etil-4-fluorfenoksi)-3,3*dimetilbutānskābe; 4-(3,4-dimetoksifenoksi)-3,3-dimetilbutānskābe; 4-(4-brom-3-metilfenoksi)-3,3-dimetilbutānskābe; 4-(3-brom-4-metilfenoksi)-3,3-dimetilbutānskābe; 4-(5,6,7,8-tetrahidronaftiloksi)-3,3-dimetilbutānskābe; 4-[4(2-metilpropil)fenoksi]-3,3-dimetilbutānskābe; 4-(4-hlor-3-etilfenoksi)-3,3-dimetilbutānskābe; 4-(4-hlor-3-metilfenoksi)-3,3-dimetilbutānskābe; 4- (4-brom-3-hlorfenoksi)-3,3-dimetilbutānskābe; 5- (4-bromfenil)-3,3-dimetilpentānskābe; 5-(3,4-dihlorfenil)-3,3-dimetilpentānskābe; 5-(4-bromfenil)-4,4-dimetilpentānskābe;
LVP-94-154A 1992-12-07 1994-08-05 Benzocycloheptenes, benzoxepines and benzothiepines and methods for preparation thereof LV10451B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9214720A FR2698873B1 (fr) 1992-12-07 1992-12-07 Benzocycloheptènes, benzoxépines et benzothiépines activateurs des canaux potassiques, procédé de préparation, composition pharmaceutique les contenant.
PCT/EP1993/003445 WO1994013658A2 (en) 1992-12-07 1993-12-07 Benzocycloheptenes, benzoxepines and benzothiepines

Publications (2)

Publication Number Publication Date
LV10451A LV10451A (lv) 1995-02-20
LV10451B true LV10451B (en) 1995-12-20

Family

ID=9436308

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-94-154A LV10451B (en) 1992-12-07 1994-08-05 Benzocycloheptenes, benzoxepines and benzothiepines and methods for preparation thereof

Country Status (29)

Country Link
US (2) US5602152A (lv)
EP (1) EP0626954B1 (lv)
JP (1) JPH07503977A (lv)
KR (1) KR100236810B1 (lv)
CN (1) CN1050127C (lv)
AT (1) ATE177742T1 (lv)
AU (1) AU680856B2 (lv)
CA (1) CA2129642A1 (lv)
CZ (1) CZ184894A3 (lv)
DE (1) DE69324001T2 (lv)
DK (1) DK0626954T3 (lv)
ES (1) ES2132373T3 (lv)
FI (1) FI943646A (lv)
FR (1) FR2698873B1 (lv)
GR (1) GR3030514T3 (lv)
HU (1) HUT67852A (lv)
IL (1) IL107891A0 (lv)
LT (1) LT3167B (lv)
LV (1) LV10451B (lv)
NO (1) NO942914L (lv)
NZ (1) NZ258896A (lv)
PL (1) PL174246B1 (lv)
RO (1) RO113040B1 (lv)
RU (1) RU2127268C1 (lv)
SI (1) SI9300632A (lv)
SK (1) SK93994A3 (lv)
TW (1) TW276255B (lv)
WO (1) WO1994013658A2 (lv)
ZA (1) ZA939127B (lv)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6107494A (en) * 1994-09-13 2000-08-22 G.D. Searle And Company Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
DK0781278T3 (da) * 1994-09-13 2001-04-17 Monsanto Co Nye benzothiepiner, som har aktivitet som inhibitorer af ileal galdsyretransport og taurocholatoptagelse
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US5952326A (en) * 1997-12-10 1999-09-14 Pfizer Inc. Tetralin and chroman derivatives useful in the treatment of asthma, arthritis and related diseases
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
WO2000038721A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
ES2200587T3 (es) 1998-12-23 2004-03-01 G.D. Searle Llc Combinaciones de inhibidors del transporte de acidos biliares del ileon e inhibidores de la proteina de transferencia de colesteril ester para indicaciones cardiovasculares.
EP1140187B1 (en) * 1998-12-23 2003-09-03 G.D. Searle LLC. Combinations of an ibat inhibitor and a mtp inhibitor for cardiovascular indications
AU2157400A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
US6569905B1 (en) 1998-12-23 2003-05-27 G.D. Searle, Llc Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
JP2002533414A (ja) 1998-12-23 2002-10-08 ジー．ディー．サール エルエルシー 心臓血管に適用するための回腸胆汁酸輸送阻害剤および胆汁酸隔離剤の組み合わせ
DE69907960T2 (de) * 1998-12-23 2004-02-26 G.D. Searle Llc, Chicago Kombinationen von ileumgallensäuretransports inhibitoren und fibronsäure derivaten für kardiovaskuläre indikationen
EA009466B1 (ru) 1998-12-23 2007-12-28 Джи.Ди. Сирл Ллс Ингибитор белка, переносящего эфир холестерила
EP1286984A2 (en) 2000-03-10 2003-03-05 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
WO2001068096A2 (en) * 2000-03-10 2001-09-20 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
US6740663B2 (en) * 2001-11-02 2004-05-25 G.D. Searle, Llc Mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
US6852753B2 (en) 2002-01-17 2005-02-08 Pharmacia Corporation Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
CN104023727B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
US20150057452A1 (en) 2012-04-04 2015-02-26 Catylix, Inc. Selective androgen receptor modulators

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1593760A1 (de) * 1967-02-01 1972-06-08 Boehringer Sohn Ingelheim Verfahren zur Herstellung neuer Benz-epinderivate
US3444176A (en) * 1967-04-28 1969-05-13 Mcneilab Inc Certain 4-diloweralkylamino-lower alkyl - 5 - pyridyl (or phenyl)-2,3-dihydro - 1 - benzothiepins and derivatives thereof
AU8402275A (en) * 1974-08-26 1977-02-17 Takeda Chemical Industries Ltd Benzocycloheptene derivatives
US4066663A (en) * 1976-07-01 1978-01-03 Syntex (U.S.A.) Inc. 6,11-Dihydrodibenzo-[b. e.]-thiepin-11-one-3-aldehyde and 3-acetal derivatives
DE3274350D1 (en) 1981-09-25 1987-01-08 Beecham Group Plc Pharmaceutically active benzopyran compounds
US4416687A (en) * 1982-02-01 1983-11-22 Monsanto Company 3,5-Bis (trifluoromethyl)phenoxy carboxylic acids and derivatives thereof
PH22343A (en) * 1983-02-15 1988-08-12 Merrell Dow Pharma 2h-(1) benzoxepino (5,4-b) 1,4-oxazine derivatives
AU597671B2 (en) * 1986-06-20 1990-06-07 Suntory Limited 2-Phenylbenzoxepin derivative
DE3726261A1 (de) 1986-12-23 1988-07-07 Merck Patent Gmbh Chromanderivate
US4971982A (en) 1987-07-06 1990-11-20 Hoffmann-La Roche Inc. Benzopyran derivatives
GB8812765D0 (en) * 1988-05-28 1988-06-29 Beecham Group Plc Novel compounds
DE3831697A1 (de) * 1988-09-17 1990-03-22 Hoechst Ag 2,3,4,5-tetrahydro-1-benzoxepine, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen
DE3922392A1 (de) * 1989-07-07 1991-01-17 Merck Patent Gmbh Chromanderivate
JP3018386B2 (ja) * 1990-01-24 2000-03-13 吉富製薬株式会社 光学活性なベンゾチエピノピリダジン化合物の製造法

Also Published As

Publication number Publication date
CN1050127C (zh) 2000-03-08
NO942914D0 (lv) 1994-08-05
PL304719A1 (en) 1995-01-09
KR100236810B1 (ko) 2000-02-01
RO113040B1 (ro) 1998-03-30
HU9402302D0 (en) 1994-10-28
LT3167B (en) 1995-02-27
FI943646A0 (fi) 1994-08-05
JPH07503977A (ja) 1995-04-27
AU680856B2 (en) 1997-08-14
DE69324001T2 (de) 1999-10-07
NZ258896A (en) 1996-03-26
RU2127268C1 (ru) 1999-03-10
TW276255B (lv) 1996-05-21
DK0626954T3 (da) 1999-10-11
ATE177742T1 (de) 1999-04-15
SI9300632A (en) 1994-09-30
CN1097752A (zh) 1995-01-25
US5602152A (en) 1997-02-11
US5652252A (en) 1997-07-29
CA2129642A1 (en) 1994-06-23
NO942914L (no) 1994-08-05
FR2698873A1 (fr) 1994-06-10
LTIP1525A (en) 1994-07-15
RU94040853A (ru) 1996-07-10
ZA939127B (en) 1994-08-05
IL107891A0 (en) 1994-04-12
DE69324001D1 (de) 1999-04-22
PL174246B1 (pl) 1998-07-31
HUT67852A (en) 1995-05-29
EP0626954A1 (en) 1994-12-07
FI943646A (fi) 1994-08-05
GR3030514T3 (en) 1999-10-29
LV10451A (lv) 1995-02-20
CZ184894A3 (en) 1995-02-15
EP0626954B1 (en) 1999-03-17
WO1994013658A3 (en) 1994-08-04
KR950700278A (ko) 1995-01-16
FR2698873B1 (fr) 1995-02-24
AU5697594A (en) 1994-07-04
ES2132373T3 (es) 1999-08-16
WO1994013658A2 (en) 1994-06-23
SK93994A3 (en) 1995-04-12

Similar Documents

Publication Publication Date Title
LV10451B (en) Benzocycloheptenes, benzoxepines and benzothiepines and methods for preparation thereof
AU582982B2 (en) Hydroxy and aminothiazolyl-benzodiazinone compounds, cardiotonic compositions including the same,and their uses
US4198421A (en) Antiinflammatory 2-substituted-dibenzo[2,3:6,7]oxepino[4,5-d]imidazoles
US4560693A (en) [1,3]-Dioxolo[4,5-f]benzimidazoles and [1,4]-dioxino[2,3-f]benzimidazoles
FI96858B (fi) Menetelmä valmistaa farmakologisesti käyttökelpoinen 6,11-dihydro-11-(4-piperidylideeni)-5H-bentso/1,2b/pyridiini
RU2114833C1 (ru) Арил-конденсированные 2,4-диазепиновые соединения, промежуточные продукты, антиаритмический агент и композиция
JPS6233161A (ja) １，５−ベンゾジアゼピン化合物
JP2707936B2 (ja) β−オキソ−β−ベンゼンプロパンチオアミド誘導体
DK168010B1 (da) Tetrahydroisoquinolinforbindelser og farmaceutisk middel indeholdende en saadan forbindelse
US3860600A (en) Octahydropyrrido{8 2,1-c{9 {8 1,4{9 benzodiazepines
CZ325196A3 (en) Derivatives of hydroximic acid, pharmaceutical compositions containing thereof, process of their preparation and intermediates used in the preparation process
JPH04244063A (ja) フエニルスルホンアミド置換されたピリジンアルケン−および−アミノオキシアルカンカルボン酸誘導体
JP3135170B2 (ja) アミノメチル置換２，３−ジヒドロピラノ〔２，３−ｂ〕ピリジン類
JPH0625151B2 (ja) ２−置換シクロヘプトイミダゾ−ル誘導体、抗潰瘍剤及びその製造方法
KR850000452B1 (ko) 카바모일옥시아미노-1, 4-벤조디아제핀의 제조방법
DK160049B (da) 6-phenethylaminoalkyl-furo-(3,4-c)-pyridin-derivater, og laegemidler indeholdende saadanne forbindelser
US6949656B2 (en) Cyclic amine derivatives and use thereof
GB2181129A (en) 9-(substituted thio)-4h-pyrido1,2-apyrimidin-4-one derivatives, their manufacture and us
EP0199096B1 (en) Nitro substituted heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them
US5308851A (en) Bispyridyl-containing heterocycles useful for treating cognitive disorders
JPH10130240A (ja) Ｉｃａｍ−１産生阻害剤
US4639457A (en) Benzocycloheptapyridone compounds for treating congestive heart failure
WO1999036408A1 (en) Novel pyrimidine derivatives
FI58915B (fi) Foerfarande foer framstaellning av 2-(2-pyridyl)-omega-fenylalkylaminer med antisekretorisk aktivitet
JPH0249727A (ja) 抗潰瘍剤